Zobrazeno 1 - 10
of 73
pro vyhledávání: '"John Wilton"'
Publikováno v:
Mineralium Deposita. 57:1089-1106
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5a4eaa7370a6087f82705d7a0d9f00c
https://doi.org/10.1007/s00126-022-01092-5
https://doi.org/10.1007/s00126-022-01092-5
Autor:
Mohammad Ghasemi, Andrew Goey, John Wilton, Wiam Bshara, Adrienne Groman, Renuka Iyer, Christos Fountzilas, Wen Wee Ma, Mateusz Opyrchal, Alex A. Adjei, Rachel Evans, Kristopher Attwood
Publikováno v:
Int J Cancer
In this phase I, dose-escalation study, we sought to determine the maximum tolerated dose (MTD) of the anaplastic lymphoma kinase/c-ROS oncogene 1 receptor (ALK/ROS1) inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1534e6c826354b62f8035b23b1faaead
https://doi.org/10.1002/ijc.33754
https://doi.org/10.1002/ijc.33754
Autor:
Ghassan K. Abou-Alfa, Peter Kuhn, Jinru Shia, James J. Harding, Christine S. Ferrer, Danny N. Khalil, Joanne F. Chou, Benjamin R. Tan, Marinela Capanu, Hooman Yarmohammadi, Mariam Rodriguez-Lee, Chayma Boussayoud, Kerri E. Muenkel, Renuka Iyer, Carmen Ruiz, Gian Kinh Do, Imane El Dika, Robin Kate Kelley, John Wilton
Publikováno v:
Oncologist
The oncologist, vol 25, iss 12
The oncologist, vol 25, iss 12
Lessons Learned Androgen receptor as assessed by immunohistochemistry is expressed in a high proportion of patients with hepatocellular carcinoma (HCC). Enzalutamide at 160 mg orally daily is safe and tolerable in patients with advanced HCC but has n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26c3de113d656d274d049b7423a4e727
https://doi.org/10.1634/theoncologist.2020-0521
https://doi.org/10.1634/theoncologist.2020-0521
Autor:
Sheryl-Ann Suffren, Chong Wang, Diane Reidy-Lagunes, Hans Minderman, Danielle Casucci, Manisha H. Shah, Karen A. Hicks, Kristopher Attwood, Sarbajit Mukherjee, Robert R. Bies, Renuka Iyer, Christos Fountzilas, Orla Maguire, John Wilton, Bhavana Konda, Dwight H. Owen
Publikováno v:
Cancer
Background Antiangiogenic-targeting agents have low response rates in patients with nonpancreatic neuroendocrine tumors (NETs). Nintedanib is an oral antiangiogenic agent that has inhibitory effects on the fibroblast growth factor receptor, which is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::781f40224b1767012dbcb89e4c355796
https://doi.org/10.1002/cncr.32994
https://doi.org/10.1002/cncr.32994
Autor:
Kristopher Attwood, John Wilton, Wiam Bshara, Katy Wang, Renuka Iyer, Medhavi Gupta, Robert R. Bies, Smitha S. Krishnamurthi, Sunyoung S. Lee, Bassam Estfan, Christos Fountzilas
Publikováno v:
Ann Transl Med
BackgroundHepatocellular carcinoma (HCC) is a major cause of cancer-related death. It is a highly vascular tumour with multiple angiogenic factors, most importantly vascular endothelial growth factor (VEGF), involved in HCC progression. Tivozanib is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55a622b52f954c4fcb41239e481d989d
https://doi.org/10.1038/s41416-020-0737-6
https://doi.org/10.1038/s41416-020-0737-6
Autor:
Barbara A. Foster, Robert A. Casero, Mikhail A. Nikiforov, Anna Bianchi-Smiraglia, Gissou Azabdaftari, Mark D. Long, Hayley C. Affronti, Roberto Pili, Ellen Karasik, Justine J. Jacobi, Anthony J. Pellerite, Michael T. Moser, Kristopher Attwood, Dominic J. Smiraglia, Bryan Gillard, John Wilton, Aryn M. Rowsam, James G. Phillips, Christoph S. Boerlin, Spencer Rosario
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
Nature Communications
Nature Communications
Prostatic luminal epithelial cells secrete high levels of acetylated polyamines into the prostatic lumen, sensitizing them to perturbations of connected metabolic pathways. Enhanced flux is driven by spermidine/spermine N1-acetyltransferase (SSAT) ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::812c63b49f1f15750014582809426b7d
https://doaj.org/article/e67ec780a1554759a4b84c3b9ee77ce5
https://doaj.org/article/e67ec780a1554759a4b84c3b9ee77ce5
Autor:
Lia Luus, Vasileios Askoxylakis, John Wilton, Alexey Lugovskoy, Kenneth J. Olivier, Stephanie Grabow, Jaeyeon Kim, Christine Pien, Geoffrey Kuesters, Suresh K. Tipparaju, Melissa Geddie, Nancy Dumont, Mark E. Hayes, Alexander Koshkaryev, Sarah A Schihl, C. Patrick Reynolds, Rachel Blaydes, Andrew J. Sawyer, James D. Marks, Tad Kornaga, James Suchy, Charles O. Noble, Dmitri B. Kirpotin, Shinji Oyama, Neeraj Kohli, Zhaohua Richard Huang, Walid S. Kamoun, Daryl C. Drummond, Yu Zhou
Publikováno v:
Nature Biomedical Engineering. 3:264-280
Antibody-mediated tumour targeting and nanoparticle-mediated encapsulation can reduce the toxicity of antitumour drugs and improve their efficacy. Here, we describe the performance of a nanotherapeutic encapsulating a hydrolytically sensitive docetax
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d8e94f819de7e7f6ccdf49b01d0fee2
https://doi.org/10.1038/s41551-019-0385-4
https://doi.org/10.1038/s41551-019-0385-4
Autor:
Charles LeVea, Grace K. Dy, Wei Tan, Laura Pitzonka, Patrick McKay Boland, Renuka Iyer, Alex A. Adjei, Hao Xie, Robert M. Straubinger, Sarah A Schihl, William E. Brady, Krystin Mantione, Amy Whitworth, Wen Wee Ma, Gerald J. Fetterly, John Wilton
Publikováno v:
American Journal of Clinical Oncology. 42:184-189
OBJECTIVES: Preclinical studies demonstrated antitumor activity of dovitinib in pancreatic cancer models. This phase Ib study aimed to determine the maximum tolerated dose of dovitinib in combination with gemcitabine and capecitabine and to character
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cc3babf7e001739ec14179f912c6003
https://doi.org/10.1097/coc.0000000000000492
https://doi.org/10.1097/coc.0000000000000492
Autor:
John J. Stocking, Michael V. Fiandalo, Gissou Azabdaftari, John Wilton, Krystin Mantione, Yun Li, Yue Wu, Elena Pop, David S. Watt, Kristopher Attwood, James L. Mohler, Elizabeth M. Wilson
Publikováno v:
Oncotarget
// Michael V. Fiandalo 1 , John J. Stocking 1 , Elena A. Pop 1 , John H. Wilton 1, 2 , Krystin M. Mantione 2 , Yun Li 1 , Kristopher M. Attwood 3 , Gissou Azabdaftari 4 , Yue Wu 1 , David S. Watt 5 , Elizabeth M. Wilson 6 and James L. Mohler 1 1 Depa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ce1cc4c46933c24b84dde182f659ca1
https://doi.org/10.18632/oncotarget.24107
https://doi.org/10.18632/oncotarget.24107
Autor:
John Wilton, Kristopher Attwood, James L. Mohler, Carol Wrzosek, Michael V. Fiandalo, Yue Wu, Krystin Mantione
Publikováno v:
The Prostate. 78:213-221
Background Almost all men who present with advanced prostate cancer (CaP) and some men who fail therapy for clinically localized CaP are treated with androgen deprivation therapy (ADT). CaP cell lines are used to identify and characterize new agents
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8da8aebe1a67ff0b54bda722fd632b1c
https://doi.org/10.1002/pros.23459
https://doi.org/10.1002/pros.23459